Richard Eisenstadt
2021 - PharmAthene
In 2021, Richard Eisenstadt earned a total compensation of $1.7M as Chief Financial Officer at PharmAthene.
Compensation breakdown
| Non-Equity Incentive Plan | $120,000 |
|---|---|
| Option Awards | $1,137,450 |
| Stock Awards | $458,000 |
| Total | $1,715,450 |
Eisenstadt received $1.1M in option awards, accounting for 66% of the total pay in 2021.
Eisenstadt also received $120K in non-equity incentive plan and $458K in stock awards.
Rankings
In 2021, Richard Eisenstadt's compensation ranked 6,678th out of 12,405 executives tracked by ExecPay. In other words, Eisenstadt earned more than 46.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,678 out of 12,405 | 46th |
Division Manufacturing | 2,889 out of 5,494 | 47th |
Major group Chemicals And Allied Products | 1,270 out of 2,369 | 46th |
Industry group Drugs | 1,132 out of 2,090 | 46th |
Industry Pharmaceutical Preparations | 822 out of 1,537 | 47th |
Source: SEC filing on August 16, 2022.
Eisenstadt's colleagues
We found four more compensation records of executives who worked with Richard Eisenstadt at PharmAthene in 2021.
News
PharmAthene CEO Vipin Garg's 2022 pay rises 9% to $2.9M
August 16, 2023
PharmAthene CEO Vipin Garg's 2021 pay jumps 83% to $2.6M
August 16, 2022
AYTU BIOPHARMA CEO Joshua Disbrow's 2021 pay jumps 291% to $6.2M
April 7, 2022
Neos Therapeutics CEO Gerald McLaughlin's 2019 pay falls 56% to $1.4M
April 21, 2020
Neos Therapeutics CEO Gerald McLaughlin receives $3.2M in 2018
April 24, 2019